SCHEMBL16713271

SCHEMBL16713271

O=C(c1cc(F)cc(F)c1)c1ccco1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.75
ALDH1A1 P00352 5/20 0.75
MEN1 O00255 2/20 0.75
POLB P06746 1/20 0.75
THRB P10828 1/20 0.75
APEX1 P27695 1/20 0.75
RECQL P46063 1/20 0.75
TDP1 Q9NUW8 1/20 0.75
CES2 O00748 2/20 0.50
CES1 P23141 2/20 0.50
GAA P10253 1/20 0.50
PTPN1 P18031 1/20 0.46
RAB9A P51151 3/20 0.44
PIM1 P11309 1/20 0.44
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15354269 0.86 ALDH1A1 (1.00) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL16713290 0.83 KMT2A (0.66) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL19367867 0.80 ERCC5 (0.54) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL29029980 0.79 KMT2A (0.85) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL16713276 0.78 KMT2A (0.75) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL30977784 0.78 KMT2A (0.75) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL181841 0.77 ALDH1A1 (0.74) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL3953437 0.76 ALDH1A1 (0.73) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL29377294 0.75 KMT2A (0.70) KMT2AALDH1A1MEN1POLBTHRB
SCHEMBL8437671 0.73 ALDH1A1 (0.68) KMT2AALDH1A1MEN1POLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3071550-B1 METHOD OF PREPARING FUSED RING INDENO COMPOUNDS TRANSITIONS OPTICAL INC (US) 2019-03-13 EP disclosed
US-9630902-B2 Method of preparing fused ring indeno compounds TRANSITIONS OPTICAL, INC. (US) 2017-04-25 US disclosed
EP-3071550-A1 METHOD OF PREPARING FUSED RING INDENO COMPOUNDS Transitions Optical, Inc. (US) 2016-09-28 EP disclosed
US-20160060205-A1 Method Of Preparing Fused Ring Indeno Compounds TRANSITIONS OPTICAL, INC. 2016-03-03 US disclosed
US-9206151-B2 Method of preparing fused ring indeno compounds TRANSITIONS OPTICAL, INC. (US) 2015-12-08 US disclosed
WO-2015077147-A1 METHOD OF PREPARING FUSED RING INDENO COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2015-05-28 WO disclosed
US-20150141662-A1 Method Of Preparing Fused Ring Indeno Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141662-A1 Method Of Preparing Fused Ring Indeno Compounds INHA, INTS9, CA9 KMT2A 1445/4885ALDH1A1 198/4885MEN1 657/4885
US-20160060205-A1 Method Of Preparing Fused Ring Indeno Compounds INHA, INTS9, CA9 KMT2A 1445/4885ALDH1A1 198/4885MEN1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.